1. Busnelli A, et al. “‘Forever young’ — Testosterone replacement therapy: A blockbuster drug despite flabby evidence and broken promises.”
Human Reprod. 2017;32(4):719–724.
2. Bandari J, et al. “Marketing and testosterone treatment in the USA: A systematic review. Eur Urol Focus. 2017;3(4-5):395-402.
3. Gupta N, et al. “Calculated free T and T:E ratio but not total testosterone and estradiol predict low libido.” Journal of Urology. 2017;197(4):e1143-e1144.
4. Abhyankar N, et al. “Testosterone to estradiol ratio correlates with sperm concentration improvement in hypogonadal oligozoosermic patients treated with anastrozole.” Fertility and Sterility. 2016;106(3) Suppl:e239–e240.
5. Linus Pauling Institute. Idole-3-Carbinol. https://lpi.oregonstate.edu/mic/dietary-factors/phytochemicals/indole-3-carbinol. Updated January 2017. Accessed October 31, 2018.
6. Smith S, et al. “3,3′-diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.” J Nutr. 2008;138(12):2379–2385.
7. Michnovicz JJ, et al. “Changes in levels of urinary estrogen metabolites after oral indole-3-carbinol treatment in humans.” J Natl Cancer Inst. 1997;89(10):718-723.
8. Smith S, et al. “3,3′-diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.” J Nutr. 2008;138(12):2379–2385.
9. Beaver LM et al. “3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.” Toxicol Appl Pharmacol. 2012 Sep 15;263(3):345-51.
10. Le HT, et al. “Plant-derived 3,3′-diindolylmethane is a strong androgen antagonist in human prostate cancer cells.” J Biol Chem. 2003;278(23):21136-21145.
11. Cumming DC, et al. “Acute suppression of circulating testosterone levels by cortisol in men.” J Clin Endocrinol Metab. 1983;57(3):671-673.
12. Bhattacharyya D, et al. “Controlled program trial of Ocimum sanctum leaf on generalized anxiety disorders.” Nepal Med Coll J. 2008;0(3):176-179.
13. Saxena RC, et al. “Efficacy of an extract of Ocimum tenuiflorum (OciBest) in the management of general stress: A double-blind, placebo-controlled study.” Evid Based Complement Alternat Med. 2012; 2012:894509.
14. Gholap S and Kar A. “Hypoglycaemic effects of some plant extracts are possibly mediated through inhibition in corticosteroid concentration.” Pharmazie. 2004;59(11):876-878.
15. Zhang Y, et al. “Irisin exerts dual effects on browning and adipogenesis of human white adipocytes.” Am J. Physio Endocrinol Metab. 2016;311(2):E530-E541.
16. Bang HS, et al. “Ursolic acid supplementation decreases markers of skeletal muscle damage during resistance training in resistance-trained men: a pilot study.” Korean J Physiol Pharmacol. 2017;21(6): 651–656.
17. Perryman RL and Thorner MO. “The effects of hyperprolactinemia on sexual and reproductive function in men.” J Androl. 1981;5:233-242.
18. Weizman A, et al. “The correlation of increased serum prolactin levels with decreased sexual desire and activity in elderly men.” J Am Geriatr Soc. 1983;31(8):485-488.
19. Paick JS, et al. “The role of prolactin levels in the sexual activity of married men with erectile dysfunction.” BJU Int. 2006;98(6):1269-1273.
20. Heskes AM, et al. “Biosynthesis of bioactive diterpenoids in the medicinal plant Vitex agnus-castus.” Plant J. 2018;93(5):943–958.
21. Ottenbacher KJ and Goodwin JS. “Trends in androgen prescribing in the United States, 2001 to 2011.” JAMA Internal Medicine. 2013;173(15):1465-1466.
22. Ottenbacher KJ and Goodwin JS. “Trends in androgen prescribing in the United States, 2001 to 2011.” JAMA Internal Medicine. 2013;173(15):1465-1466.
23. Traish A. “Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?” Investig Clin Urol. 2016;57(6):384-400.
24. Statista. “Annual testosterone drug revenue in the U.S. in 2013 and 2018 (in billion U.S. dollars).”
https://www.statista.com/statistics/320301/predicted-annual-testosterone-drug-revenues-in-the-us/
25. Busnelli A, et al. “‘Forever young’ — Testosterone replacement therapy: A blockbuster drug despite flabby evidence and broken promises.” Human Reprod. 2017;32(4):719–724.